Eagle Pharmaceuticals Inc (EGRX) concluded trading on Wednesday at a closing price of $2.14, with 4.66 million shares of worth about $9.97 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -55.97% during that period and on October 02, 2024 the price saw a loss of about -39.89%. Currently the company’s common shares owned by public are about 12.99M shares, out of which, 11.43M shares are available for trading.
Stock saw a price change of -44.85% in past 5 days and over the past one month there was a price change of -54.08%. Year-to-date (YTD), EGRX shares are showing a performance of -59.08% which decreased to -85.93% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.21 but also hit the highest price of $15.69 during that period. The average intraday trading volume for Eagle Pharmaceuticals Inc shares is 105.08K. The stock is currently trading -47.15% below its 20-day simple moving average (SMA20), while that difference is down -51.71% for SMA50 and it goes to -56.02% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Eagle Pharmaceuticals Inc (NASDAQ: EGRX) currently have 12.99M outstanding shares and institutions hold larger chunk of about 76.76% of that.
The stock has a current market capitalization of $27.80M and its 3Y-monthly beta is at 0.51. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EGRX, volatility over the week remained 17.64% while standing at 11.67% over the month.
EPS is likely to grow at an annualized rate of 2.70% for next 5-years, compared to annual growth of -3.56% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on August 10, 2023 offering an Underweight rating for the stock and assigned a target price range of between $26 and $17 to it. Coverage by Piper Sandler stated Eagle Pharmaceuticals Inc (EGRX) stock as an Underweight in their note to investors on August 09, 2023, suggesting a price target of $17 for the stock. Stock get a Neutral rating from Piper Jaffray on October 31, 2018.
